Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China
Crossref DOI link: https://doi.org/10.1007/s12325-019-00908-7
Published Online: 2019-03-21
Published Print: 2019-05
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Guan, Haijing
Sheng, Yanan
Guo, Wanjie
Han, Sheng
Shi, Luwen http://orcid.org/0000-0003-2683-6685
Text and Data Mining valid from 2019-03-21
Article History
Received: 10 January 2019
First Online: 21 March 2019